Form 8-K Tracon Pharmaceuticals, For: Sep 27
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
TRACON Pharmaceutical (TCON) Offers Additional Detail on Janssen Licensing Agreement
September 28, 2016 4:41 PM EDTTRACON Pharmaceutical (NASDAQ: TCON) disclosed the following in a U.S. SEC filing on Wednesday:
Item 1.01 - Entry into a Material Definitive Agreement.
On September 27, 2016, TRACON Pharmaceuticals, Inc. (the Company) entered into separate transactions with Janssen Pharmaceutica N.V. (Janssen) and its affiliate, Johnson & Johnson Innovation-JJDC, Inc. (JJDC) consisting of a license and option agreement with Janssen (the License and Option Agreement) and a stock purchase agreement and investor agreement, each with JJDC (the Stock Purchase Agreement and the Investor Agreement, respectively).
License and Option Agreement
Under the License and Option Agreement, Janssen granted the... More
